Skip to main content

Table 1 Demographic Characteristics of the Patients by Treatment Groups

From: Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial

Characteristicsa All patients (n = 100) Arbidol group (n = 50) KALETRA group (n = 50)
Age, years (SD)b 56.4 (16.3) 56.6 (17.8) 56.2 (14.8)
Sex, n (%) 100 (100) 50 (100) 50 (100)
 Male, n (%) 60 (60) 33 (66) 27 (54)
 Female, n (%) 40 (40) 17 (34) 23 (46)
Marital status, n (%) 100 (100) 50 (100) 50 (100)
 Single, n (%) 39 (39) 19 (38) 20 (40)
 Married, n (%) 61 (61) 31 (62) 30 (60)
Job, n (%) 90 (100) 44 (100) 46 (100)
 Hospital staff, n (%) 5 (5.5) 1 (2.3) 4 (8.7)
 Self-employment, n (%) 32 (35.5) 16 (36.4) 16 (34.8)
 Housekeeper, n (%) 35 (38.9) 15 (34.1) 20 (43.5)
 Worker, n (%) 5 (5.6) 4 (9.1) 1 (2.2)
 Employee, n (%) 13 (14.4) 8 (18.2) 5 (10.9)
Smoker, n (%) 15 (15) 12 (24) 3 (6)
Cigarette per day, n (SD) 12.2 (11.9) 13.5 (12.4) 5 (4.2)
Smoking duration, years (SD) 14.6 (8.2) 14.5 (8.6) 15 (7)
Comorbidities, n (%) 72 (72) 39 (78) 33 (66)
 Hypertension, n (%) 39 (39) 22 (44) 17 (34)
 Diabetes, n (%) 28 (28) 15 (30) 13 (26)
 Coronary heart disease, n (%) 9 (9) 7 (14) 2 (4)
 Asthma, n (%) 2 (2) 2 (4) 0 (0)
 Chronic kidney disease, n (%) 2 (2) 1 (2) 1 (2)
 Other diseases, n (%) 38 (38) 22 (44) 16 (32)
  1. aData is presented as mean (standard deviation), n (%) or n (SD); bAbbreviation: SD standard deviation